CB-012 allogeneic anti-CLL-1 CAR-T cell therapy

CB-012, a genome-edited allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking

CB-012, a genome-edited allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking

Format

PNG

Quelle:

Caribou Biosciences, Inc.

Downloads